Market Cap 14.54B
Revenue (ttm) 8.28B
Net Income (ttm) 791.47M
EPS (ttm) N/A
PE Ratio 15.43
Forward PE 15.25
Profit Margin 9.56%
Debt to Equity Ratio 0.36
Volume 1,165,400
Avg Vol 1,024,448
Day's Range N/A - N/A
Shares Out 80.76M
Stochastic %K 19%
Beta 1.23
Analysts Strong Sell
Price Target $214.21

Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and p...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 353 1 291 2000
Fax: 353 1 247 6260
Address:
South County Business Park, Leopardstown, Dublin, Ireland
JarvisFlow
JarvisFlow Oct. 24 at 4:44 PM
TD Cowen has adjusted their stance on Icon ( $ICLR ), setting the rating to Hold with a target price of 183 → 172.
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 1:44 PM
Barclays has updated their rating for Icon ( $ICLR ) to Equal-Weight with a price target of 185.
0 · Reply
topstockalerts
topstockalerts Oct. 23 at 7:17 PM
Medpace’s Strong Quarter Signals Biotech Recovery Medpace Holdings reported third-quarter new orders of $789 million, up 49% year-over-year, with revenue of $659.9 million and earnings of $3.86 per share—well above forecasts. The results indicate renewed momentum in biotech after years of slowdown. The company’s backlog grew 2.5% from 2024 levels, suggesting improving conditions for small and midsize biotech firms. Shares jumped over 10% Thursday following a premarket surge of more than 17%. The SPDR S&P Biotech ETF has risen 20% since September, far outpacing the S&P 500’s 4% gain. Sector optimism has been fueled by M&A activity and easing policy concerns, including President Trump’s recent drug pricing deal with Pfizer. Analysts say Medpace’s strong bookings and improved funding conditions for clients show the biotech recovery is gaining traction. $MEDP $XBI $SPX $PFE $ICLR
0 · Reply
mugachasamuel
mugachasamuel Oct. 23 at 1:01 PM
$ICLR 🩸 to ungodly levels
0 · Reply
1986iamwallstreet
1986iamwallstreet Oct. 23 at 11:55 AM
$ICLR let it bleed 🩸
0 · Reply
mugachasamuel
mugachasamuel Oct. 23 at 10:29 AM
$ICLR $160 or lower 🩸
1 · Reply
mugachasamuel
mugachasamuel Oct. 23 at 6:26 AM
$ICLR need $160
0 · Reply
mugachasamuel
mugachasamuel Oct. 22 at 11:57 PM
$ICLR hii nayo imenipiga linga mbaya
0 · Reply
1986iamwallstreet
1986iamwallstreet Oct. 22 at 8:30 PM
$ICLR below 160 in play
0 · Reply
ChessGM
ChessGM Oct. 20 at 12:47 AM
$ICLR "Heads up alert! Only three days until Upcoming earnings on Wednesday, 10/22/2025 for $ICLR Bearish (3.2) Financial Analysis: ICON Public Limited Company (NASDAQ: ICLR) is currently under scrutiny due to several factors impacting its stock performance. The company's P/E ratio has been pressured recently, aligning with its peer average within the contract research organization (CRO) sector. However, a recent downgrade by Jefferies, which altered its rating from Buy to Hold, highlights concerns over ICON’s customer retention and competitive positioning. The downgrade was accompanied by a reduced price target from $220 to $175, reflecting a more cautious outlook on future growth prospects and revenue generation capabilities. The EPS growth has been lackluster compared to industry peers such as IQVIA and Charles River, which have been favored by analysts due to stronger client pipelines and operational efficiencies. Despite stable financial guidance for 2025, uncertainties surrounding leadership transitions and recent weak results have raised questions about ICON’s short-term strategic execution. Revenue forecasts suggest moderate growth, but competitive pressures could hinder substantial upside. Investors may need to weigh these factors carefully against the backdrop of a dynamic CRO landscape. Earnings Report Outlook: As ICON prepares for its third-quarter 2025 earnings, expectations are tempered. Analysts project modest revenue and EPS figures, reflecting the headwinds the company faces. Historically, ICON has managed to meet or slightly exceed earnings estimates, but the current climate of leadership changes and competitive market dynamics adds layers of complexity. The upcoming earnings report will be closely watched for any deviations from the company’s stable guidance, as well as insights into how new leadership will navigate these challenges. Analysts' consensus estimates suggest a cautious stance, with potential impacts on the stock depending significantly on management's commentary and future outlook. Sector Performance: The broader contract research organization (CRO) sector, to which ICON belongs, has demonstrated resilience, with some firms outperforming due to strategic client acquisitions and robust service offerings. While ICON faces specific challenges, the sector overall is benefiting from increased demand for outsourced clinical trial and drug development services. Competitors like IQVIA and Charles River have capitalized on this environment, receiving favorable analyst ratings and showcasing strong financial performances. The sector’s performance highlights the importance of strategic positioning and client relationship management, areas where ICON will need to focus to improve its standing and investor confidence. - Funds were net sellers of $ICLR during the previous reporting quarter. - Funds with large holdings in $ICLR include: - Alyeska Investments, MV: $25MM. Fund Rank: 79% - Adage Capital P, MV: $5MM. New position. Fund Rank: 89% www.adagecapital.com - Last 10 days performance: 1% - Last 30 days performance: 8% - Last 90 days performance: 31% Some of the latest news articles: - Title: With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case Publication Date: 10/17/2025 3:45:03 PM, Source: yahoo URL: https://finance.yahoo.com/news/eps-growth-more-icon-nasdaq-154503951.html?.tsrc=rss - Title: Is It Time To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)? Publication Date: 10/1/2025 10:30:39 AM, Source: yahoo URL: https://finance.yahoo.com/news/time-consider-buying-icon-public-103039686.html?.tsrc=rss - Title: ICON Public Limited Company (ICLR) Fell Due to Weak Results and an Uncertain Outlook Publication Date: 9/26/2025 12:52:51 PM, Source: yahoo URL: https://finance.yahoo.com/news/icon-public-limited-company-iclr-125251165.html?.tsrc=rss - Title: ICON plc Schedules Third Quarter 2025 Earnings Conference Call Publication Date: 9/24/2025 1:00:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/icon-plc-schedules-third-quarter-130000836.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
0 · Reply
Latest News on ICLR
ICON Reports Third Quarter 2025 Results

Oct 22, 2025, 4:25 PM EDT - 2 days ago

ICON Reports Third Quarter 2025 Results


ICON: Solid Fundamentals Trump Regulatory Headwinds

Oct 22, 2025, 4:38 AM EDT - 3 days ago

ICON: Solid Fundamentals Trump Regulatory Headwinds


ICON plc Schedules Third Quarter 2025 Earnings Conference Call

Sep 24, 2025, 9:00 AM EDT - 4 weeks ago

ICON plc Schedules Third Quarter 2025 Earnings Conference Call


ICON Announces CEO Transition

Sep 4, 2025, 8:00 AM EDT - 7 weeks ago

ICON Announces CEO Transition


ICON plc to Participate at Upcoming Investor Conferences

Sep 2, 2025, 6:00 AM EDT - 7 weeks ago

ICON plc to Participate at Upcoming Investor Conferences


ICON: Lower Guidance Downside And Expanded Repurchase Plan

Jul 24, 2025, 7:00 AM EDT - 3 months ago

ICON: Lower Guidance Downside And Expanded Repurchase Plan


ICON Announces Results of Annual General Meeting

Jul 23, 2025, 4:20 PM EDT - 3 months ago

ICON Announces Results of Annual General Meeting


ICON Reports Second Quarter 2025 Results

Jul 23, 2025, 4:15 PM EDT - 3 months ago

ICON Reports Second Quarter 2025 Results


ICON plc Schedules Second Quarter 2025 Earnings Conference Call

Jun 23, 2025, 6:30 AM EDT - 4 months ago

ICON plc Schedules Second Quarter 2025 Earnings Conference Call


ICON releases its ICON Cares 2024 Report

May 19, 2025, 4:15 PM EDT - 5 months ago

ICON releases its ICON Cares 2024 Report


ICON Reports First Quarter 2025 Results

Apr 30, 2025, 4:15 PM EDT - 6 months ago

ICON Reports First Quarter 2025 Results


GreensKeeper Q1 2025 Portfolio Update

Apr 10, 2025, 8:55 AM EDT - 7 months ago

GreensKeeper Q1 2025 Portfolio Update

AXP CHKP ELV GOOG GOOGL ICE VRTX


ICON plc Schedules First Quarter 2025 Earnings Conference Call

Mar 31, 2025, 6:30 AM EDT - 7 months ago

ICON plc Schedules First Quarter 2025 Earnings Conference Call


ICON plc to Present at Upcoming Investor Conferences

Mar 5, 2025, 7:30 AM EST - 8 months ago

ICON plc to Present at Upcoming Investor Conferences


JarvisFlow
JarvisFlow Oct. 24 at 4:44 PM
TD Cowen has adjusted their stance on Icon ( $ICLR ), setting the rating to Hold with a target price of 183 → 172.
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 1:44 PM
Barclays has updated their rating for Icon ( $ICLR ) to Equal-Weight with a price target of 185.
0 · Reply
topstockalerts
topstockalerts Oct. 23 at 7:17 PM
Medpace’s Strong Quarter Signals Biotech Recovery Medpace Holdings reported third-quarter new orders of $789 million, up 49% year-over-year, with revenue of $659.9 million and earnings of $3.86 per share—well above forecasts. The results indicate renewed momentum in biotech after years of slowdown. The company’s backlog grew 2.5% from 2024 levels, suggesting improving conditions for small and midsize biotech firms. Shares jumped over 10% Thursday following a premarket surge of more than 17%. The SPDR S&P Biotech ETF has risen 20% since September, far outpacing the S&P 500’s 4% gain. Sector optimism has been fueled by M&A activity and easing policy concerns, including President Trump’s recent drug pricing deal with Pfizer. Analysts say Medpace’s strong bookings and improved funding conditions for clients show the biotech recovery is gaining traction. $MEDP $XBI $SPX $PFE $ICLR
0 · Reply
mugachasamuel
mugachasamuel Oct. 23 at 1:01 PM
$ICLR 🩸 to ungodly levels
0 · Reply
1986iamwallstreet
1986iamwallstreet Oct. 23 at 11:55 AM
$ICLR let it bleed 🩸
0 · Reply
mugachasamuel
mugachasamuel Oct. 23 at 10:29 AM
$ICLR $160 or lower 🩸
1 · Reply
mugachasamuel
mugachasamuel Oct. 23 at 6:26 AM
$ICLR need $160
0 · Reply
mugachasamuel
mugachasamuel Oct. 22 at 11:57 PM
$ICLR hii nayo imenipiga linga mbaya
0 · Reply
1986iamwallstreet
1986iamwallstreet Oct. 22 at 8:30 PM
$ICLR below 160 in play
0 · Reply
ChessGM
ChessGM Oct. 20 at 12:47 AM
$ICLR "Heads up alert! Only three days until Upcoming earnings on Wednesday, 10/22/2025 for $ICLR Bearish (3.2) Financial Analysis: ICON Public Limited Company (NASDAQ: ICLR) is currently under scrutiny due to several factors impacting its stock performance. The company's P/E ratio has been pressured recently, aligning with its peer average within the contract research organization (CRO) sector. However, a recent downgrade by Jefferies, which altered its rating from Buy to Hold, highlights concerns over ICON’s customer retention and competitive positioning. The downgrade was accompanied by a reduced price target from $220 to $175, reflecting a more cautious outlook on future growth prospects and revenue generation capabilities. The EPS growth has been lackluster compared to industry peers such as IQVIA and Charles River, which have been favored by analysts due to stronger client pipelines and operational efficiencies. Despite stable financial guidance for 2025, uncertainties surrounding leadership transitions and recent weak results have raised questions about ICON’s short-term strategic execution. Revenue forecasts suggest moderate growth, but competitive pressures could hinder substantial upside. Investors may need to weigh these factors carefully against the backdrop of a dynamic CRO landscape. Earnings Report Outlook: As ICON prepares for its third-quarter 2025 earnings, expectations are tempered. Analysts project modest revenue and EPS figures, reflecting the headwinds the company faces. Historically, ICON has managed to meet or slightly exceed earnings estimates, but the current climate of leadership changes and competitive market dynamics adds layers of complexity. The upcoming earnings report will be closely watched for any deviations from the company’s stable guidance, as well as insights into how new leadership will navigate these challenges. Analysts' consensus estimates suggest a cautious stance, with potential impacts on the stock depending significantly on management's commentary and future outlook. Sector Performance: The broader contract research organization (CRO) sector, to which ICON belongs, has demonstrated resilience, with some firms outperforming due to strategic client acquisitions and robust service offerings. While ICON faces specific challenges, the sector overall is benefiting from increased demand for outsourced clinical trial and drug development services. Competitors like IQVIA and Charles River have capitalized on this environment, receiving favorable analyst ratings and showcasing strong financial performances. The sector’s performance highlights the importance of strategic positioning and client relationship management, areas where ICON will need to focus to improve its standing and investor confidence. - Funds were net sellers of $ICLR during the previous reporting quarter. - Funds with large holdings in $ICLR include: - Alyeska Investments, MV: $25MM. Fund Rank: 79% - Adage Capital P, MV: $5MM. New position. Fund Rank: 89% www.adagecapital.com - Last 10 days performance: 1% - Last 30 days performance: 8% - Last 90 days performance: 31% Some of the latest news articles: - Title: With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case Publication Date: 10/17/2025 3:45:03 PM, Source: yahoo URL: https://finance.yahoo.com/news/eps-growth-more-icon-nasdaq-154503951.html?.tsrc=rss - Title: Is It Time To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)? Publication Date: 10/1/2025 10:30:39 AM, Source: yahoo URL: https://finance.yahoo.com/news/time-consider-buying-icon-public-103039686.html?.tsrc=rss - Title: ICON Public Limited Company (ICLR) Fell Due to Weak Results and an Uncertain Outlook Publication Date: 9/26/2025 12:52:51 PM, Source: yahoo URL: https://finance.yahoo.com/news/icon-public-limited-company-iclr-125251165.html?.tsrc=rss - Title: ICON plc Schedules Third Quarter 2025 Earnings Conference Call Publication Date: 9/24/2025 1:00:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/icon-plc-schedules-third-quarter-130000836.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 2:03 PM
Barclays updates rating for Icon ( $ICLR ) to Equal-Weight, target set at 180 → 190.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 29 at 11:05 AM
$ICLR Excellent article that nails exactly where ICLR stands right now. So if you want to update your ICLR knowledge or get acquainted with ICLR, this is a must read. https://beyondspx.com/quote/ICLR/analysis/icon-s-strategic-ascent-fueling-pharma-s-future-with-innovation-and-scale-nasdaq-iclr
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 12:13 PM
$ICLR: SWEEP PUT contracts spotted 8 @ 36.01, Strike 200.0, Exp 1/16/2026, Premium $28,804, Sentiment BEARISH
0 · Reply
FlashClimb
FlashClimb Sep. 15 at 10:09 AM
$ICLR Short-term volatility likely; long-term hinges on margin expansion
0 · Reply
RunnerSignals
RunnerSignals Sep. 12 at 4:05 AM
Daily Market Pulse $ORCL $WDC $LION $ICLR $CLF dancing to new highs with party in the charts! https://stocksrunner.com/news/2025-09-11-daily-market-pulse-advanced-technical-analysis-for-key-stock-trading-strategies
0 · Reply
topstockalerts
topstockalerts Sep. 9 at 7:29 PM
Jefferies upgraded IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. IQVIA was named top pick, with stronger client wins, stable trends, and less reliance on single customers; price target raised to $225. ICON faces client losses, project cancellations near $ 1B in Q3, and biotech weakness, leading to a price target cut to $175. Charles River gained on stronger bookings, safety-testing demand, and potential value from a manufacturing unit sale, with a $195 target. Jefferies stayed cautious on Medpace (valuation) and Fortrea (execution risks). $IQV $CRL $ICLR $ICON
1 · Reply
anachartanalyst
anachartanalyst Sep. 9 at 12:02 PM
$ICLR https://anachart.com/wp-content/uploads/ana_temp/1757419294_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Sep. 9 at 11:00 AM
Jefferies has updated their rating for Icon ( $ICLR ) to Hold with a price target of 175.
0 · Reply
DonCorleone77
DonCorleone77 Sep. 4 at 3:51 PM
$ICLR Icon confirms financial guidance for FY25
0 · Reply
smartkarma
smartkarma Jul. 30 at 11:05 AM
$ICLR | ICON plc: Initiation of Coverage- Capitalizing On Opportunities in China, A Critical Growth Market! "ICON Plc's second-quarter results for 2025 reveal a mixed landscape in the clinical development sector. The company reported revenue of $2.017..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/icon-plc-initiation-of-coverage-capitalizing-on-opportunities-in-china-a-critical-growth-market
0 · Reply
JarvisFlow
JarvisFlow Jul. 25 at 5:26 PM
Mizuho has adjusted their stance on Icon ( $ICLR ), setting the rating to Outperform with a target price of 173 → 225.
0 · Reply
JarvisFlow
JarvisFlow Jul. 25 at 3:28 PM
UBS has adjusted their stance on Icon ( $ICLR ), setting the rating to Buy with a target price of 170 → 240.
0 · Reply